Mechanisms of plaque instability and stabilization

Therapeutic Research

Volumn 23, Issue 12, 2002, Pages 2387-2428

  Libby, Peter ^a   Aikawa, Masanori ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ATENOLOL; COLLAGEN; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOSARTAN;

APOPTOSIS; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONFERENCE PAPER; HEART MUSCLE ISCHEMIA; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INFECTION; INSULIN RESISTANCE; LIFESTYLE; METABOLIC DISORDER; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; SMOOTH MUSCLE FIBER; THROMBOGENICITY; THROMBOSIS;

EID: 0036951941     PISSN: 02898020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (216)

1. Libby P. The molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
2. Hackett D, Davies G, Maseri A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J 1988;9:1317-23.
3. Smith S, Jr. Risk-reduction therapy: the challenge to change. Circulation 1996;93:2205-11.
4. Bruschke AV, Kramer J Jr., Bal ET, Haque IU, Detrano RC, Goormastic M. The dynamics of progression of coronary atherosclerosis studied in 168 medically treated patients who underwent coronary arteriography three times. Am Heart J 1989;117:296-305.
5. Yokoya K, Takatsu H, Suzuki T, Hosokawa H, Ojio S, Matsubara T, et al. Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: a study based on four serial coronary arteriograms per year. Circulation 1999;100:903-9.
6. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000;343:915-22.
7. Davies MJ, Thomas T. The pathological basis and microanatomy of occlusive thrombus formation in human coronary arteries. Philos Trans R Soc Lond B Biol Sci 1981;294:225-9.
8. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983;50:127-34.
9. Constantinides P. Plaque hemorrhages, their genesis and their role in supraplaque thrombosis and atherogenesis. In: Glagov S, Newman WPI, Schaffer SA, eds. Pathobiology of the Human Atherosclerotic Plaque. New York: Springer-Verlag; 1989. p.393-412.
10. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the unstable plaque. Prog Cardiovasc Dis 2002;44:349-56.
11. Libby P. Lesion versus lumen. Nat Med 1995;1:17-8.
12. Glagov S, Weisenberg E, Zarins C, Stankunavicius R, Kolletis G. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:371-5.
13. Clarkson TB, Prichard RW, Morgan TM, Petrick GS, Klein KP. Remodeling of coronary arteries in human and nonhuman primates. JAMA 1994;271:289-94.
14. Siegel RJ, Ariani M, Fishbein MC, Chae JS, Park JC, Maurer G, et al. Histopathologic validation of angioscopy and intravascular ultrasound. Circulation 1991;84:109-17.
15. Uchida Y, Nakamura F, Tomaru T, Morita T, Oshima T, Sasaki T, et al. Prediction of acute coronary syndromes by percutaneous coronary angioscopy in patients with stable angina. Am Heart J 1995;130:195-203.
16. Ziada KM, Kapadia SR, Tuzcu EM, Nissen SE. The current status of intravascular ultrasound imaging. Curr Probl Cardiol 1999;24:541-66.
17. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 2000;101:598-603.
18. Tuzcu EM, Hobbs RE, Rincon G, Bott-Silverman C, De Franco AC, Robinson K, et al. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation: insights from intravascular ultrasound. Circulation 1995;91:1706-13.
19. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate intersitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1991;11:1223-30.
20. Rekhter M, Zhang K, Narayanan A, Phan S, Schork M, Gordon D. Type I collagen gene expression in human atherosclerosis: localization to specific plaque regions. Am J Pathol 1993;143:1634-48.
21. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.Circulation 1994;89:36-44.
22. Hansson GK, Jonasson L, Holm J, Clowes MK, Clowes A. Gamma interferon regulates vascular smooth muscle proliferation and Ia expression in vivo and in vitro. Circ Res 1988;63:712-9.
23. Warner SJC, Friedman GB, Libby P. Regulation of major histocompatibility gene expression in cultured human vascular smooth muscle cells. Arteriosclerosis 1989;9:279-88.
24. Lendon CL, Davies MJ, Born GV, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 1991;87:87-90.
25. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-81.
26. Geng Y-J, Libby P. Evidence for apoptosis in advanced human atheroma: co-localization with interleukin-1 b-converting enzyme. Am J Pathol 1995;147:251-66.
27. Han D, Haudenschild C, Hong M, Tinkle B, Leon M, Liau G. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol 1995;147:267-77.
28. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation 1995;91:2703-11.
29. Geng Y-J, Wu Q, Muszynski M, Hansson G, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1-beta. Arterioscler Thromb Vasc Biol 1996;16:19-27.
30. Geng Y-J, Henderson L, Levesque E, Muszynski M, Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed humann vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:2200-8.
31. Brinckerhoff CE, Matrisian LM. TIMELINE: Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-14.
32. Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
33. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;9:2503-9.
34. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001;104:1899-904.
35. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996;271:1544-50.
36. Galis Z, Muszynski M, Sukhova G, Simon-Morrisey E, Unemori E, Lark M, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994;75:181-9.
37. Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001;107:1117-26.
38. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
39. Galis Z, Kranzhoefer R, Fenton JI, Libby P. Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:483-9.
40. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for athero-sclerotic plaque stability. J Clin Invest 1996;98:2572-9.
41. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991;88:8154-8.
42. Schoenbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 1999;189:843-53.
43. Fukumoto Y, Libby P, Rabkin E, Varo N, Harada K, Hill CC, et al. Genetically determined resistance to collagenase action alters content of collagen and smooth muscle cells in atheroma [abstract]. J Am Coll Cardiol 2002;39(5;Suppl. A):Abstract 410-1.
44. Farb A, Burke A, Tang A, Liang Y, Mannan P, Smialek J, et al. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996;93:1354-63.
45. Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998;97:2110-6.
46. Libby P, Ganz P, Schoen FJ, Lee RT. The vascular biology of the acute coronary syndromes. In: Topol EJ, ed. Acute Coronary Syndromes. 2 ed. New York: Marcel Dekker, Inc.; 2000. p. 33-57.
47. Slowik MR, Min W, Ardito T, Karsan A, Kashgarian M, Pober JS. Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by interleukin-1-converting enzyme-like protease-dependent and -independent pathways. Lab Invest 1997;77:257-67.
48. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5.
49. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 1995;92:2730-4.
50. Virchow R. Cellular Pathology. London: John Churchill; 1858.
51. Giachelli CM, Liaw L, Murry CE, Schwartz SM, Almeida M. Osteopontin expression in cardiovascular diseases. Ann NY Acad Sci 1995;760:109-26.
52. Demer LL, Tintut Y. Osteopontin. Between a rock and a hard plaque. Circ Res 1999;84:250-2.
53. Qiao JH, Tripathi J, Mishra NK, Cai Y, Tripathi S, Wang XP, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997;150:1687-99.
54. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the athero-sclerotic plaque. Proc Natl Acad Sci USA 1989;86:2839-43.
55. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134:1087-97.
56. Nemerson Y, Giesen PL. Some thoughts about localization and expression of tissue factor. Blood Coagul Fibrinolysis 1998;9(Suppl 1):S45-7.
57. Schonbeck U, Mach F, Sukhova GK, Herman M, Graber P, Kehry MR, et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 2000;156:7-14.
58. Edgington TS, Mackman N, Fan ST, Ruf W. Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Fr Hematol 1992;34:S15-27.
59. Mach F, Schoenbeck U, Bonnefoy J-Y, Pober J, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997;96:396-9.
60. Sobel BE. The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes. Proc Assoc Am Physicians 1999;111:313-8.
61. Berliner J, Leitinger N, Watson A, Huber J, Fogelman A, Navab M. Oxidized lipids in atherogenesis: formation, destruc- tion and action. Thromb Haemost 1997;78:195-9.
62. Lusis AJ. Atherosclerosis. Nature 2000;407(6801):233-41.
63. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001;104:503-16.
64. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
65. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725-9.
66. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987;84:5928-31.
67. GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447-55.
68. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
69. MRC/Bhf Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
70. Regnstrom J, Walldius G, Nilsson S, Elinder KS, Johansson J, Molgaard J, et al. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis 1996;125:217-29.
71. Hazen SL, Hsu FF, Gaut JP, Crowley JR, Heinecke JW. Modification of proteins and lipids by myeloperoxidase. Methods Enzymol 1999;300:88-105.
72. Heinecke JW. Is lipid peroxidation relevant to atherogenesis? J Clin Invest 1999;104:135-6.
73. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001;158:879-91.
74. Libby P. Managing the risk of atherosclerosis: the role of high-density lipoprotein. Am J Cardiol 2001;88:3N-8N.
75. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, et al. The Yin and Yang of oxidation in the develop- ment of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16:831-42.
76. Navab M, Hama SY, Hough GP, Hedrick CC, Sorenson R, La DB, et al. High density associated enzymes: their role in vascular biology. Curr Opin Lipidol 1998;9:449-56.
77. Dichtl W, Nilsson L, Goncalves I, Ares MP, Banfi C, Calara F, et al. Very low-density lipoprotein activates nuclear factor-kappa B in endothelial cells. Circ Res 1999;84:1085-94.
78. Scanu AM, Nakajima K, Edelstein C. Apolipoprotein(a): structure and biology. Front Biosci 2001;6:D546-54.
79. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002;105:1429-35.
80. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002;90:E58-65.
81. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999;100:1223-9.
82. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998;83:952-9.
83. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19:1623-9.
84. Kranzhofer R, Browatzki M, Schmidt J, Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999;257:826-8.
85. Rocha R, Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 2002;62:723-31.
86. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-8.
87. Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, et al. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 2002;39:614-8.
88. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195-200.
89. Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21:961-7.
90. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141-6.
91. Ginsberg HN, Illingworth DR. Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol 2001;88:9H-15H.
92. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. Evaluation and management of atherogenic dyslipidemia: beyond low-density lipoprotein cholesterol. CMAJ 2001;165:1331-3.
93. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-6.
94. Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 2001;110:103-10.
95. Fontbonne A. Why can high insulin levels indicate a risk for coronary heart disease? Diabetologia 1994;37:953-5.
96. Fontbonne A. Insulin-resistance syndrome and cardiovascular complications of non-insulin-dependent diabetes mellitus. Diabetes Metab 1996;22:305-13.
97. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
98. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997;46 (Suppl 2):S19-25.
99. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489-97.
100. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510-6.
101. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, et al. Acute hyperglycemia attenuates endo- thelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695-701.
102. Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vaso- dilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998;31:552-7.
103. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996;27:567-74.
104. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97:22-8.
105. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001;18:945-59.
106. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA. Inhibition of protein kinase C beta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 2002;90:107-11.
107. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-75.
108. Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med 2000;45:391-418.
109. Christen WG, Ridker PM. Blood levels of homocysteine and atherosclerotic vascular disease. Curr Atheroscler Rep 2000;2:194-9.
110. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
111. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-6.
112. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997;96:4095-103.
113. Ridker PM. Are associations between infection and coronary disease causal or due to confounding? Am J Med 1999;106:376-7.
114. Epstein SE, Zhou YE Zhu J. Potential role of cytomegalovirus in the pathogenesis of restenosis and atherosclerosis. Am Heart J 1999;138:S476-8.
115. Kol A, Sperti G, Shani J, Schulhoff N, van de Greef W, Landini MP, et al. Cytomegalovirus replication is not a cause of instability in unstable angina. Circulation 1995;91:1910-3.
116. Kalayoglu MV, Byrne GI. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun 1998;66:5067-72.
117. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage TNF-alpha and matrix metalloproteinase expression. Circulation 1998;98:300-7.
118. Kol A, Libby P. The mechanisms by which infectious agents may contribute to atherosclerosis and its clinical manifestations. Trends Cardiovasc Med 1998;8:191-9.
119. Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 1999;103:571-7.
120. Kalayoglu MV, Hoerneman B, LaVerda D, Morrison SG, Morrison RP, Byrne GI. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis 1999;180:780-90.
121. Kol A, Lichtman AH, Finberg RW, Libby P, A. Kurt-Jones, EA. Heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol 2000;164:13-7.
122. Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993;341:255-9.
123. Moazed TC, Kuo C, Grayston JT, Campbell LA. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997;175:883-90.
124. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 1998;177:1322-5.
125. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-6.
126. Caligiuri G, Rottenberg M, Nicoletti A, Wigzell H, Hansson GK. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation 2001;103:2834-8.
127. Rokitansky K. The Organs of Circulation. A Manual of Pathological Anatomy. Philadelphia: Blanchard and Lea; 1855. p.201-8.
128. Duguid J. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol 1946;58:208-12.
129. Smith EB. Fibrin deposition and fibrin degradation products in atherosclerotic plaques. Thromb Res 1994;75:329-35.
130. Bini A, Kudryk BJ. Fibrinogen in human atherosclerosis. Ann NY Acad Sci 1995;748:461-71; DISCUSSION 71-3.
131. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999;96:11023-7.
132. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4.
133. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-72.
134. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99:779-85.
135. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998;280:2001-7.
136. Paffenbarger RS Jr, Lee IM. Intensity of physical activity related to incidence of hypertension and all-cause mortality: an epidemiological view. Blood Press Monit 1997;2:115-23.
137. Paffenbarger R. Physical exercise to reduce cardiovascular disease risk. Proc Nutr Soc 2000;59:421-2.
138. Rockhill B, Willett WC, Manson JE, Leitzmann MF, Stampfer MJ, Hunter DJ, et al. Physical activity and mortality: a prospective study among women. Am J Public Health 2001;91:578-83.
139. Manson JE, Hu FB, Rich-Edwards JW, Colditz GA, Stampfer MJ, Willett WC, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999;341:650-8.
140. Oliver MF. Might treatment of hypercholesterolaemia increase non-cardiac mortality? Lancet 1991;337:1529-31.
141. S Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
142. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9.
143. LiPiD Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
144. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
145. Serruys PW, De Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22.
146. Aikawa M, Rabkin E, Okada Y, Voglic S, Clinton S, Brinckerhoff C, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998;97:2433-44.
147. Aikawa M, Voglic SJ, Sugiyama S, Rabkin E, Taubman MB, Fallon JT, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999;100:1215-22.
148. Aikawa M, Rabkin E, Voglic SJ, Shing H, Nagai R, Schoen FJ, et al. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ Res 1998;83:1015-26.
149. Aikawa M, Sugiyama S, Voglic SJ, Rabkin E, Fukumoto Y, Hill CC, et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002;106:1390-6.
150. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35.
151. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266-71.
152. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-5.
153. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myo- cardium in normocholesterolemic rat hearts. Circulation 1999;100:178-84.
154. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001;108:1429-37.
155. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001;49:281-7.
156. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:556-62.
157. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83.
158. Fukumoto Y, Aikawa M, Bourcier T, Rabkin E, Shiomi M, Libby P. Cerivastatin reduces PAI-1 expression in atheroma of WHHL rabbits (Abstract). Circulation 2000;102:II-299.
159. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:993-9.
160. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the cholesterol and recurrent events (CARE) investigators. Circulation 1999;100:230-5.
161. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
162. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
163. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
164. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
165. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
166. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7.
167. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.
168. Marx N, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk 2001;8:203-10.
169. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93.
170. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998;393:790-3.
171. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125-31.
172. Marx N, Mackman N, Schonbeck U, Yilmaz N, Hombach VV, Libby P, et al. PPAR alpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 2001;103:213-9.
173. Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, et al. PPAR alpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001;103:207-12.
174. Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002;90:703-10.
175. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, et al. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 2000;87:516-21.
176. Bocan TM, Krause BR, Rosebury WS, Mueller SB, Lu X, Dagle C, et al. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2000;20:70-9.
177. Tall AR, Jiang X, Luo Y, Silver D. 1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:1185-8.
178. Moriyama Y, Okamura T, Inazu A, Doi M, Iso H, Mouri Y, et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998;27:659-67.
179. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917-23.
180. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999;22:347-51.
181. Brooks-Wilson A, Marcil M, Clee S, Zhang LH, Romp C, van Dam M, et al. Mutations in the ATP binding cassette (ABC1) transporter gene in tangier disease and familial HDL deficiency. Nat Genet 1999;22:336-45.
182. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999;22:352-5.
183. Lamas GA, Pfeffer MA. Left ventricular remodeling after acute myocardial infarction: clinical course and beneficial effects of angiotensin-converting enzyme inhibition. Am Heart J 1991;121:1194-202.
184. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr., Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
185. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
186. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
187. Griendling KK, Harrison DG. Out, damned dot: studies of the NADPH oxidase in atherosclerosis. J Clin Invest 2001;108:1423-4.
188. Cataliotti A, Boerrigter G, Chen HH, Jougasaki M, Costello, LC, Tsuruda T, et al. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation 2002;105:639-44.
189. Corti R, Burnett JC, Jr., Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001;104:1856-62.
190. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
191. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.
192. Yanagisawa M, Kurihara H, Kurihara S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
193. d'Uscio LV, Barton M, Shaw S, Luscher TF. Endothelin in atherosclerosis: importance of risk factors and therapeutic implications. J Cardiovasc Pharmacol 2000;35:S55-9.
194. Clozel M. Endothelin receptor antagonist. Heart Fail Rev 2001;6(4):249-51.
195. Patrono C. Aspirin: new cardiovascular uses for an old drug. Am J Med 2001;110:62S-65S.
196. Schoenbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human athero- sclerotic lesions. Am J Pathol 1999;155:1281-91.
197. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
198. Libby P, Maroko PR, Bloor CM, Sobel BE, Braunwald E. Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest 1973;52:599-607.
199. Brown EJ, Jr., Kloner RA, Schoen FJ, Hammerman H, Hale S, Braunwald E. Scar thinning due to ibuprofen administration after experimental myocardial infarction. Am J Cardiol 1983;51:877-83.
200. Silverman HS, Pfeifer MP. Relation between use of anti-inflammatory agents and left ventricular free wall rupture during acute myocardial infarction. Am J Cardiol 1987;59:363-4.
201. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000;16:505-11.
202. Azar RR, Rinfret S, Theroux P, Stone PH, Dakshinamurthy R, Feng YJ, et al. A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapy with methylprednisolone in unstable angina (MUNA trial). Eur Heart J 2000;21:2026-32.
203. Muhlestein JB. Bacterial infections and atherosclerosis. J Investig Med 1998;46:396-402.
204. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
205. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997;350:404-7.
206. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000;102:1755-60.
207. Dunne MW. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial. J Infect Dis 2000;181(Suppl 3):S572-8.
208. Jackson LA. Description and status of the azithromycin and coronary events study (ACES). J Infect Dis 2000;181 (Suppl 3):S579-81.
209. Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002;89:860-1.
210. Valantine HA, Luikart H, Doyle R, Theodore J, Hunt S, Oyer P, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001;72:1647-52.
211. Mann DL. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev 2001;6:71-80.
212. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103:1044-7.
213. Schonbeck U, Libby P. Matrix metalloproteinases and their inhibitors. In: Fuster V, ed. Assessing and modifying the vulnerable atherosclerotic plaque. Armonk: Futura Publishing Company; 2002 (In press).
214. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997;17:439-44.
215. Carmeliet P, Moons L, Dewerchin M, Rosenberg S, Herbert JM, Lupu F, et al. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol 1998;140:233-45.
216. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999;100:1148-50.